DDI & Polymorphism

Combined impact of drug-drug interaction and CYP polymorphism

Age of patient

Age >= 2 years

Age < 2 years  ( months)

Age

months

Adult

substrate

Start typing the name of a drug or scroll down the list to choose one

CYP metabolism is a minor pathway for the elimination of this drug. No relevant interaction with CYP inhibitors or inducers is expected.
Glucuronidation is a major pathway for the elimination of this drug. No relevant interaction with CYP inhibitors is expected. Some inducers (e.g. rifampicin) may lower its exposure.

substrate

Fraction metabolized by each CYP
Adults
Children
 
Warning!

Interactor

Start typing the name of a drug or scroll down the list to choose one

interactor

Induction or Inhibition potency with respect to each CYP
 
Warning!

Genotypes

 

AUC ratios

Phenotype
Genotype
 
Show AUC ratios' interindividual distribution (5th to 95th percentiles)
 
Reset

Definitions

AUCXM*
AUC of the substrate given with an inhibitor or an inducer
AUCXM* / AUCXM
This ratio is useful for adapting the dose of the substrate in a patient in whom an optimal dose had been found but an interacting drug is added to the current treatment.
AUCXM* / AUCEM
This ratio is useful for adapting the initial dose of the substrate to be given to a patient whose genotype is known.